Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi-1 expression

British Journal of Pharmacology

Volumn 171, Issue 19, 2014, Pages 4440-4454

  Dong, Qinghua ^a   Chen, Long ^a   Lu, Qunwei ^b   Sharma, Sherven ^c   Li, Lei ^d   Morimoto, Sachio ^d   Wang, Guanyu ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; DOXORUBICIN; OXIDOREDUCTASE; PROTEIN BCL 2; PROTEIN BID; PROTEIN P47; PROTEIN P53; QUERCETIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; SMALL INTERFERING RNA; SUPEROXIDE DISMUTASE; ANTINEOPLASTIC ANTIBIOTIC; ANTIOXIDANT; BMI1 PROTEIN, MOUSE; CARDIOTONIC AGENT; ONCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG EFFECT; EMBRYO; ENZYME ACTIVITY; FEMALE; HEART DISEASE; HEART FUNCTION; HEART MUSCLE CELL; HEART PROTECTION; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; C57BL MOUSE; CELL LINE; DRUG EFFECTS; GENETICS; HEART MUSCLE; LIVER; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; APOPTOSIS; CARDIOTONIC AGENTS; CARDIOTOXICITY; CELL LINE; DOXORUBICIN; FEMALE; LIPID PEROXIDATION; LIVER; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE, INBRED C57BL; MITOCHONDRIA; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; POLYCOMB REPRESSIVE COMPLEX 1; PROTO-ONCOGENE PROTEINS; QUERCETIN; RATS; REACTIVE OXYGEN SPECIES;

EID: 84927633441     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12795     Document Type: Article

References (55)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, et al. (2013), The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 1449-1458.
2. Angeloni C, Spencer JP, Leoncini E, Biagi PL, Hrelia S, (2007). Role of quercetin and its in vivo metabolites in protecting H9c2 cells against oxidative stress. Biochimie 89: 73-82.
3. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM, (2000). Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 60: 1789-1792.
4. Bruynzeel AM, Abou El Hassan MA, Schalkwijk C, Berkhof J, Bast A, Niessen HW, et al. (2007). Anti-inflammatory agents and monoHER protect against doxorubicin-induced cardiotoxicity and accumulation of CML in mice. Br J Cancer 96: 937-943.
5. Chatoo W, Abdouh M, David J, Champagne MP, Ferreira J, Rodier F, et al. (2009). The polycomb group gene Bmi1 regulates antioxidant defenses in neurons by repressing p53 pro-oxidant activity. J Neurosci 29: 529-542.
6. Dong Q, Oh JE, Chen W, Kim R, Kim RH, Shin KH, et al. (2011). Radioprotective effects of Bmi-1 involve epigenetic silencing of its target genes and enhanced DNA repair in normal human keratinocytes. J Invest Dermatol 131: 1216-1225.
7. Doroshow JH, Locker GY, Myers CE, (1980). Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 65: 128-135.
8. Ertuʇ PU, Aydinoglu F, Goruroglu Ozturk O, Singirik E, Ögülener N, (2013). Comparative study of the quercetin, ascorbic acid, glutathione and superoxide dismutase for nitric oxide protecting effects in mouse gastric fundus. Eur J Pharmacol 698: 379-387.
9. Faraonio R, Vergara P, Di Marzo D, Pierantoni MG, Napolitano M, Russo T, et al. (2006). p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem 281: 39776-39784.
10. Feridooni T, Hotchkiss A, Remley-Carr S, Saga Y, Pasumarthi KB, (2011). Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes. PLoS ONE 6: e22801.
11. Filipe P, Morlière P, Patterson LK, Hug GL, Mazière JC, Freitas JP, (2004). Oxygen-copper (II) interplay in the repair of semi-oxidized urate by quercetin bound to human serum albumin. Free Radic Res 38: 295-301.
12. Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, et al. (2011). Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med 2011: 591356.
13. Gieni RS, Ismail IH, Campbell S, Hendzel MJ, (2011). Polycomb group proteins in the DNA damage response: a link between radiation resistance and 'stemness'. Cell Cycle 10: 883-894.
14. Ginjala V, Nacerddine K, Kulkarni A, Oza J, Hill SJ, Yao M, et al. (2011). BMI1 is recruited to DNA breaks and contributes to DNA damage-induced H2A ubiquitination and repair. Mol Cell Biol 31: 1972-1982.
15. Green PS, Leeuwenburgh C, (2002). Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta 1588: 94-101.
16. Ismail IH, Andrin C, McDonald D, Hendzel MJ, (2010). BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. J Cell Biol 191: 45-60.
17. Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K, et al. (2006). Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 12: 446-451.
18. Kaiserova H, Simunek T, van der Vijgh WJ, Bast A, Kvasnickova E, (2007). Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase. Biochim Biophys Acta 1772: 1065-1074.
19. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S, (2002). Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234-235: 119-124.
20. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
21. 2+ increase are reciprocally modulated in rat cardiomyocytes. Exp Mol Med 38: 535-545.
22. Kuznetsov AV, Margreiter R, Amberger A, Saks V, Grimm M, (2011). Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death. Biochim Biophys Acta 1813: 1144-1152.
23. Kyaw M, Yoshizumi M, Tsuchiya K, Izawa Y, Kanematsu Y, Tamaki T, (2004). Atheroprotective effects of antioxidants through inhibition of mitogen-activated protein kinases. Acta Pharmacol Sin 25: 977-985.
24. Lebrecht D, Walker UA, (2007). Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol 7: 108-113.
25. Lee JC, Kim J, Park JK, Chung GH, Jang YS, (2003). The antioxidant, rather than prooxidant, activities of quercetin on normal cells: quercetin protects mousethymocytes from glucose oxidase-mediated apoptosis. Exp Cell Res 291: 386-397.
26. Lee SB, Bae IH, Bae YS, Um HD, (2006). Link between mitochondria and NADPH oxidase 1 isozyme for the sustained production of reactive oxygen species and cell death. J Biol Chem 281: 36228-36235.
27. L'Ecuyer T, Sanjeev S, Thomas R, Novak R, Das L, Campbell W, et al. (2006). DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 291: H1273-H1280.
28. Li JZ, Yu SY, Wu JH, Shao QR, Dong XM, (2012). Paeoniflorin protects myocardial cell from doxorubicin-induced apoptosis through inhibition of NADPH oxidase. Can J Physiol Pharmacol 90: 1569-1575.
29. Liu J, Liu C, Chen J, Song S, Lee IH, Quijano C, et al. (2009). Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 459: 387-392.
30. Matouk AI, Taye A, Heeba GH, El-Moselhy MA, (2013). Quercetin augments the protective effect of losartan against chronic doxorubicin cardiotoxicity in rats. Environ Toxicol Pharmacol 36: 443-450.
31. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
32. Miller FJ Jr, Gutterman DD, Rios CD, Heistad DD, Davidson BL, (1998). Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 82: 1298-1305.
33. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
34. Mojzisová G, Sarisský M, Mirossay L, Martinka P, Mojzis J, (2009). Effect of flavonoids on daunorubicin-induced toxicity in H9c2 cardiomyoblasts. Phytother Res 23: 136-139.
35. Molofsky AV, He S, Bydon M, Morrison SJ, Pardal R, (2005). Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 19: 1432-1437.
36. Morales J, Günther G, Zanocco AL, Lemp E, (2012). Singlet oxygen reactions with flavonoids. A theoretical-experimental study. PLoS ONE 7: e40548.
37. Mukhopadhyay P, Rajesh M, Ba'tkai S, Kashiwaya Y, Hasko G, Liaudet L, et al. (2009). Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 296: 1466-1483.
38. Oliveira PJ, Santos MS, Wallace KB, (2006). Doxorubicin-induced thiol-dependent alteration of cardiac mitochondrial permeability transition and respiration. Biochemistry (Mosc) 71: 194-199.
39. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, et al. (2003). Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423: 302-305.
40. Park J, Park E, Ahn BH, Kim HJ, Park JH, Koo SY, et al. (2012). NecroX-7 prevents oxidative stress-induced cardiomyopathy by inhibition of NADPH oxidase activity in rats. Toxicol Appl Pharmacol 263: 1-6.
41. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Research 42 (Database Issue): D1098-1106.
42. Pei TX, Xu CQ, Li B, Zhang ZR, Gao XX, Yu J, et al. (2007). Protective effect of quercetin against adriamycin-induced cardiotoxicity and its mechanism in mice. Yao Xue Xue Bao 42: 1029-1033.
43. Peng X, Chen B, Lim CC, Sawyer DB, (2005). The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv 5: 163-171.
44. Pereira GC, Silva AM, Diogo CV, Carvalho FS, Monteiro P, Oliveira PJ, (2011). Drug induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. Curr Pharm Des 17: 2113-2129.
45. Sag CM, Wagner S, Maier LS, (2013). Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes. Free Radic Biol Med 63: 338-349.
46. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS, (2002). BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 4: 842-849.
47. Sharma V, Mishra M, Ghosh S, Tewari R, Basu A, Seth P, et al. (2007). Modulation of interleukin-1 beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection. Brain Res Bull 3: 55-63.
48. 2+ release by sarcoplasmic reticulum in skinned muscle fibers. Proc Natl Acad Sci USA 77: 4435-4438.
49. Silber JH, Barber G, (1995). Doxorubicin-induced cardiotoxicity. N Engl J Med 333: 1359-1360.
50. Staedler D, Idrizi E, Kenzaoui BH, Juillerat-Jeanneret L, (2011). Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol 68: 1161-1172.
51. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML, (1991). Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266: 1672-1677.
52. Tsutsui H, Ide T, Kinugawa S, (2006). Mitochondrial oxidative stress, DNA damage, and heart failure. Antioxid Redox Signal 8: 1737-1744.
53. Wallace KB, (2003). Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 93: 105-115.
54. Wang G, Zhang J, Liu L, Sharma S, Dong Q, (2012). Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS ONE 12: e51764.
55. Yoshida M, Shiojima I, Ikeda H, Komuro I, (2009). Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 47: 698-705.